SOURCE: ChromoCure, Inc.

May 20, 2010 08:30 ET

Genome Research Group and ChromoCure Prepare for HHS' $1 Billion ARRA Funds for Research Labs: Grants to Advance Research Nationwide

LONDON--(Marketwire - May 20, 2010) -  ChromoCure, Inc. (Genome Research Group, Inc.) (PINKSHEETS: KKUR) announced today its planned US Research Grant Centres. This program is in direct in response to the US Department of Health and Human Services' (HHS) $1 billion in American Recovery and Reinvestment Act funds for the construction, repair, and renovation of biomedical research labs across the country.

U.S. Health and Human Services Secretary Kathleen Sebelius announced May 14th $1 billion of American Recovery and Reinvestment Act funds have been awarded to construct, repair and renovate scientific research laboratories and related facilities across the country.

The National Institutes of Health (NIH) National Center for Research Resources (NCRR) administered the grants, which are expected to create or sustain jobs nationwide and to help foster scientific advances that may lead to improved human health.

"This unprecedented Recovery Act investment in research facility construction will not only give our world-class scientists the modern facilities they need for impact research, it will also help create and maintain jobs in varied business sectors and in all regions of our country," said Secretary Sebelius.

This announcement adds further impetus to the worldwide increase in medical genome research that has emerged since The Mayo Clinic published its landmark findings confirming aneuploidy as the cause of cancer in the December 2009 Cancer Cell journal. This publication has spurred increased worldwide research by a number of respected research universities and institutions, all of which have published similar reports in 2010, and is cited to be one of the contributing factors behind Walgreens' recently announced mail-in genetic testing kits to be offered at 7,500 of their retail locations nationwide.

The Company's cancer detection technology is based on the chromosomal theory of cancer. Research has conclusively and irrefutably demonstrated aneuploidy a more accurate predictor of cancer than cytological/histological analysis or genetic marker-based diagnostics that are the only other methods in existence today.

The Company's cancer detection system locates and measures unique genomic characteristics found in 100% of all cancers and never found in normal cells. The Company's detection technology has an effective 100% accuracy rate and an effective 100% specificity therefore making "false positives" and "false negatives" theoretically impossible.

This announcement, together with the recently announced addition of Full Spectrum ChromoSomal Scan Capability for Broad Base Cancer Progression Assessment: Further Enhancing Detection & Progression Monitoring, the Clinical Testing and Trials for its landmark ChromoSomal Scanning Technology as applied to cervical cancer and the Euro Zone launch of its Pathologist Collaborative Research (PCR) Program in support of the groundbreaking Project Boveri: Find the Cure Initiative, further establishes the Company's leading role in the new era of cancer research, detection, and therapy, as the companies leverage their combined technologies, research knowledge and industry relationships.

The Company possesses advanced detection and therapeutic technology and protocols, comprised of ChromoCure's advanced detection system and GRG's full line of therapeutic protocols and technology, allowing for the first time real-time progression monitoring and remission detection -- providing the world's first cure research fully integrated system for the precise measurement of treatment and on-demand, real-time cancer progression analysis to monitor and determine treatment efficacy.

The Company's combined technologies have been validated in clinical trials and provide the foundation for significant advances in diagnosis, therapy and cure, and placed the Company at the forefront of both cancer detection and research. Shareholders can expect further updates on research and testing collaborations, laboratory partnerships, and research initiatives.

Management believes these initiatives to be of significant long-term shareholder value and furthers the Company's transition to research, technology development, and licensing as a source of significant long-term and recurring revenues and equity appreciation.

About Genome Research Group, Inc. (ChromoCure, Inc.)
The Company develops and provides proprietary cancer detection systems and related therapeutic technologies. The Company's proprietary cancer detection system locates and measures unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has a proven and effective accuracy of 100% for all cancers at all stages. The Company's proprietary Therapeutic Modeling Protocols provide statistical modeling and prediction tools for the measurement and monitoring of cancer progression and remission. The Company also applies its technology and knowledge to cancer cure and therapeutics research.

The Company owns proprietary cancer detection systems and related therapeutic technologies and proprietary techniques for non-toxic and non-invasive cancer therapy utilizing hypothermic modulation and resonance. The Company's proprietary CS200 Chromosomal Scanner has been proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has an effective accuracy of 100% for all cancers at all stages. GRG's advanced Therapeutic Modeling and Treatment Protocols, combined with its industry and medical research collaborations, validate its leadership role in Cancer Detection, Therapy and Cure.

The Company believes its technology will become the worldwide gold standard for cancer detection, progression measurement, and research for both therapy and cure. The Company also applies its technology and knowledge to cancer cure and therapeutics research.

Safe-Harbor Statement
 
This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated on the Company's website "investors" section by reference) and should be read before any investment decision.  

Contact Information